Tag: litigation

Singapore , June 05, 2025 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”, “YYGH”, or the “Company”), is pleased to announce the acquisition of Uniforce Security Pte Ltd (UFS), marking a pivotal step in expanding the Company’s Integrated Facility Management (IFM) division. This strategic acquisition underscores the Company’s commitment to delivering comprehensive, cutting-edge solutions to clients worldwide.

BOCA RATON, FL , June 05, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Amber International Holding Limited (Nasdaq: AMBR) (“Amber International”), a leading provider of institutional crypto financial services and solutions and operating under the brand name "Amber Premium."

De nouvelles données à long terme issues de l’étude CARTITUDE-1 montrent qu’un tiers des patients traités par cilta-cel restent sans progression de la maladie à cinq ans¹

COLUMBUS, Ohio, June 05, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced that as of 5:00 p.m., New York City time, on June 4, 2025 (the “Early Participation Date”), pursuant to and in accordance with its previously announced cash tender offer (the “Tender Offer”), approximately $536,786,000 in aggregate principal amount of the Company’s 9.750% Senior Notes due 2029 (the “Notes”) had been validly tendered and not validly withdrawn on or prior to the Early Participation Date, which, if and when accepted for purchase up to $150,000,000 in aggregate principal amount of Notes (the “Tender Cap”) by the Company pursuant to the terms and conditions of the Tender Offer, would result in Total Consideration (as defined below) (excluding accrued interest payable) of $1,071.25 for each $1,000 principal amount of Notes, which Total Consideration was determined in accordance with the terms of the Tender Offer based on the principal amount of Notes tendered and the Bid Premiums (as defined in the Offer to Purchase (as defined below)) at which such tenders were made.

Combination Delivers Unmatched Innovation in Arm-based Vulnerability and Malware Research, Smart Device DevSecOps and Mobile Pen Testing

New leadership focuses on business simplification and brand enablers

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants et des conjugués anticorps-médicaments (Biclonics^®, Triclonics^® et ADClonics^®), a annoncé aujourd’hui le lancement d’une offre publique de souscription de ses actions ordinaires (les « Actions de l’offre »). Toutes les actions ordinaires sont proposées par Merus. En outre, Merus prévoit d’accorder aux souscripteurs une option de 30 jours leur permettant d’acheter jusqu’à 15 % supplémentaires des Actions de l’offre (les « Actions optionnelles » et collectivement avec les Actions de l’offre, les « Actions »). L’offre est soumise aux conditions du marché et à d’autres conditions de clôture. Aucune garantie ne saura être donnée quant au fait que l’offre sera réalisée ni le moment auquel cela interviendra ou encore sa taille réelle ou ses modalités.

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.